Literature DB >> 4039986

A comparison of the thrombolytic and hemorrhagic effects of tissue-type plasminogen activator and streptokinase in rabbits.

G Agnelli, M R Buchanan, F Fernandez, B Boneu, J Van Ryn, J Hirsh, D Collen.   

Abstract

Tissue-type plasminogen activator (t-PA) is a promising thrombolytic agent because it can produce thrombolysis without inducing a plasma proteolytic state. It is uncertain if this potentially important feature renders t-PA less hemorrhagic than other plasminogen activators. We have compared the hemorrhagic and thrombolytic effects of t-PA and streptokinase in rabbits. Streptokinase, 4000 U/kg/hr over 4 hr, failed to produce significant thrombolysis and 8000 U/kg/hr streptokinase over 4 hr produced only 28 +/- 6% thrombolysis. Both streptokinase regimens were associated with a plasmin-mediated plasma proteolytic state and both streptokinase regimens produced a significant increase in hemorrhage that was evident within 15 min of beginning the infusion and was progressive over the 4 hr of drug administration. In contrast, t-PA in a dose of 7500 U/kg/hr produced 35 +/- 6% thrombolysis, but it did not produce a plasmin-mediated plasma proteolytic state or a significant increase in hemorrhage over the 4 hr of infusion. t-PA in a dose of 15,000 U/kg/hr produced 85 +/- 4% thrombolysis but was associated with a plasmin-mediated proteolytic state and produced significant bleeding which, in contrast to streptokinase-induced bleeding, was delayed in onset. Therefore, t-PA induced less hemorrhage than streptokinase at doses that produced more effective thrombolysis. Bleeding with both thrombolytic agents was associated with a plasmin-mediated proteolytic state.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4039986     DOI: 10.1161/01.cir.72.1.178

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  12 in total

Review 1.  Use of plasminogen activators in venous thrombosis.

Authors:  J Hirsh; A G Turpie
Journal:  World J Surg       Date:  1990 Sep-Oct       Impact factor: 3.352

2.  Intravitreal recombinant tissue plasminogen activator in the treatment of experimentally induced bacterial endophthalmitis.

Authors:  N Baziuk; T Fang; G A Peyman; C M Gremillion
Journal:  Int Ophthalmol       Date:  1991-03       Impact factor: 2.031

Review 3.  Back to the future: so what will fibrinolytic therapy offer your patients with myocardial infarction?

Authors:  J R Mitchell
Journal:  Br Med J (Clin Res Ed)       Date:  1986-04-12

4.  Tissue-type plasminogen activator. Therapeutic potential in thrombotic disease states.

Authors:  D Collen
Journal:  Drugs       Date:  1986-01       Impact factor: 9.546

Review 5.  Trends and future developments in the pharmacological treatment of acute ischaemic stroke.

Authors:  G J del Zoppo; S Wagner; M Tagaya
Journal:  Drugs       Date:  1997-07       Impact factor: 9.546

Review 6.  Pharmacokinetic optimisation of the treatment of deep vein thrombosis.

Authors:  A Iorio; G Agnelli
Journal:  Clin Pharmacokinet       Date:  1997-02       Impact factor: 6.447

Review 7.  Tissue-type plasminogen activator. A review of its pharmacology and therapeutic use as a thrombolytic agent.

Authors:  D Collen; H R Lijnen; P A Todd; K L Goa
Journal:  Drugs       Date:  1989-09       Impact factor: 9.546

8.  Divergent disease patterns in granulocyte-macrophage colony-stimulating factor transgenic mice associated with different transgene insertion sites.

Authors:  D Metcalf; J G Moore
Journal:  Proc Natl Acad Sci U S A       Date:  1988-10       Impact factor: 11.205

9.  The effects of recombinant tissue-type plasminogen activator (rt-PA) on canine cadaver lung transplantation.

Authors:  S Akasaka; H Nishi; M Aoe; H Date; A Andou; N Shimizu
Journal:  Surg Today       Date:  1999       Impact factor: 2.549

Review 10.  Thrombolytic therapy in the treatment of stroke.

Authors:  G J del Zoppo
Journal:  Drugs       Date:  1997       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.